New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
12:16 EDTTPX, HAIN, SRPT, SWKSOptions with increasing implied volatility: SRPT TPX SWKS HAIN
News For SRPT;TPX;SWKS;HAIN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 26, 2014
10:07 EDTTPXHigh option volume stocks
Subscribe for More Information
November 25, 2014
16:01 EDTHAINHain Celestial announces 2 for 1 stock split
The Hain Celestial Group announced that its stockholders had approved an increase in the number of authorized shares of the company's common stock from 100M shares to 150M shares. The company's Board of Directors had previously approved a 2 for 1 stock split in the form of a 100% dividend subject to approval by stockholders to increase the company's authorized shares. Stockholders of record at the close of business on December 12 will receive one additional share of Hain Celestial common stock for every one share of Hain Celestial common stock owned on that date. The additional shares are expected to be distributed on or about December 29.
08:51 EDTSRPTSarepta outlook unchanged after BioMarin deal, says Roth Capital
Subscribe for More Information
08:03 EDTSRPTSarepta to host conference call
Subscribe for More Information
07:49 EDTTPXTempur Sealy share gains likely to continue, says BofA/Merrill
BofA/Merrill said Tempur's North American sales have been impressive and gained share in Q3. The firm expects Tumpur to report earnings growth above the industry for the next two years and sees further upside from greater-than-expected Sealy synergies and debt pay down. Shares are Buy rated with a $61 price target.
November 24, 2014
16:34 EDTSRPTOn The Fly: Closing Wrap
Stocks on Wall Street opened in quiet fashion and trading remained that way throughout the day. The Dow and S&P moved in a narrow range and hugged the flat line, while the Nasdaq drifted steadily higher and added nearly 1% by the close of trade. ECONOMIC EVENTS: In the U.S., the Chicago Fed national activity index fell to 0.14 in October, versus expectations for a reading of 0.33. Markit's services PMI fell to 56.3 in the flash reading for November, versus expectations for a slight increase to 57.3 from its prior reading of 57.1. The Dallas Fed manufacturing index was steady at 10.5 in November, versus expectations for a 9.0 reading. Overseas, the euro areas largest economy, Germany, saw a business climate index advance to 104.7 in November from 103.2 in October, beating economists' prediction for a decline to a reading of 103. COMPANY NEWS: Apple (AAPL) had a role in the Nasdaq's outperformance, as the tech giant climbed after a number of research firms, including Susquehanna, Cantor and KGI Research, were upbeat on the outlook for the company's performance during the holiday season. The iPhone maker's stock rose $2.15, or 1.85%, to close at $118.62 to close just below the 52-week high of $118.77 it hit late in the session... United Technologies (UTX) fell $1.51, or 1.37%, to $108.79 after the Dow member announced that Louis Chenevert had retired as Chairman and CEO, effective immediately. The company reaffirmed its expectations for 2014 earnings per share and sales, but provided little information regarding the abrupt exit of the executive. MAJOR MOVERS: Among the notable gainers was Prosensa (RNA), which surged $7.16, or 62.59%, to $18.60 after the small drugmaker agreed to be acquired by larger BioMarin (BMRN). After the deal announcement BioMarin shares also rose $2.11, or 2.46%, to $87.94, while Sarepta Therapeutics (SRPT), which is working on a Duchenne muscular dystrophy treatment to rival Prosensa's, advanced 88c, or 5.59%, to $16.61. Also higher was Cimatron (CIMT), which jumped $2.57, or 42.27%, to $8.65 after 3D Systems (DDD) agreed to buy the company for approximately $97M, or $8.97 per share, in cash. Among the noteworthy losers was Ring Energy (REI), which fell $1.28, or 9.54%, to $12.14 after Canaccord downgraded the stock to Hold from Buy, citing the the recent decline in crude oil prices and the potential need for the company to raise capital. Also lower were shares of Potash (POT), which fell $2.23, or 6.09%, to $34.40, and Mosaic (MOS), which slid $1.75, or 3.71%, to $45.46 after Russia's Uralkali, the world's largest potash producer, was reported to be set to start repair work at part of its damaged mine. INDEXES: The Dow added 7.84, or 0.04%, to 17,817.90, the Nasdaq rose 41.92, or 0.89%, to 4,754.89, and the S&P 500 gained 5.91, or 0.29%, to 2,069.41.
12:59 EDTSRPTOn The Fly: Midday Wrap
Subscribe for More Information
12:21 EDTSRPTBioMarin rises after agreeing to buy DMD drug maker Prosensa
Subscribe for More Information
10:00 EDTHAINOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:23 EDTSRPTOn The Fly: Pre-market Movers
Subscribe for More Information
09:20 EDTSRPTProsensa buyout not good for Sarepta, says Piper Jaffray
Piper Jaffray says it views the Prosensa (RNA) acquisition by BioMarin (BMRN) as bad for Sarepta (SRPT) since the company now has to compete with a "significantly more experienced and better funded orphan drug player." Piper adds that the takeover announced this morning has no impact on Sarepta's current drug filing process for its Duchenne muscular dystrophy drug eteplirsen. It keeps a Neutral rating on Sarepta with a $20 price target. The stock is trading up 9% in pre-market trading to $17.16 after BioMarin paid a healthy premium to acquire its peer Prosensa.
08:12 EDTSRPTSarepta rises after DMD competitor acquired at significant premium
Shares of Sarepta Therapeutics (SRPT) are up 9.5% to $17.23 in early pre-market trading after rival drugmaker Prosensa (RNA) agreed to be acquired by BioMarin (BMRN). BioMarin has offered to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680M. In addition, two approximately $80M contingent milestones are payable for the approval of drisapersen in the U.S. and Europe. Drisapersen is Prosensa's lead exon-skipping drug candidate for treating Duchenne muscular dystrophy, or DMD. Sarepta is at work on eteplirsen, its own exon-skipping therapeutic candidate for the treatment of DMD. Prosensa closed trading Friday at $11.44 and are up about 65% to $18.90 in pre-market trading following the deal announcement.
06:32 EDTHAINHain Celestial initiated with a Buy at Longbow
Subscribe for More Information
November 20, 2014
15:14 EDTSRPTTraveler returned from Mali being tested for Ebola in NYC, Daily News reports
Subscribe for More Information
November 18, 2014
09:17 EDTSRPTSarepta announces first patient dosed in Eteplirsen study
Subscribe for More Information
November 17, 2014
16:43 EDTTPXTempur Sealy appoints Jay Spenchian as Chief Marketing Officer
Subscribe for More Information
08:48 EDTSWKSSkyworks, Avago, and RF Micro Devices recommended at BofA/Merrill
Subscribe for More Information
08:44 EDTSRPTNebraska Medical announces death of third Ebola patient
The Nebraska Medical Center said via Twitter, "We are sorry to announce that the 3rd Ebola patient, Dr. Martin Salia, has passed away as a result of the advanced symptoms of the disease." Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
November 14, 2014
16:52 EDTTPXGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
06:22 EDTHAINHain Celestial price target raised to $127 from $114 at Citigroup
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use